Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides
- 30 November 1991
- journal article
- review article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 27 (11) , 1466-1471
- https://doi.org/10.1016/0277-5379(91)90033-a
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Antisense oligonucleotides: gene regulation and chemotherapy of AIDSAdvanced Drug Delivery Reviews, 1991
- Cellular uptake of antisense oligodeoxynucleotidesAdvanced Drug Delivery Reviews, 1991
- RNA enzymes (ribozymes) as antiviral therapeutic agentsTrends in Biotechnology, 1990
- The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locusNature, 1990
- Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotideThe Lancet, 1990
- Comparative activity of α- and β-anomeric oligonucleotides on rabbit β globin synthesis: Inhibitory effect of cap targeted α-oligonucleotidesBiochemical and Biophysical Research Communications, 1989
- Synthesis of alkylating oligonucleotide derivatives containing cholesterol or phenazinium residues at their 3′‐terminus and their interaction with DNA within mammalian cellsFEBS Letters, 1989
- Specific inhibition of lymphokine biosynthesis and autocrine growth using antisense oligonucleotides in Th1 and Th2 helper T cell clones.The Journal of Experimental Medicine, 1988
- Complementary addressed modification of double‐stranded DNA within a ternary complexFEBS Letters, 1988
- Sequence-Specific Cleavage of Double Helical DNA by Triple Helix FormationScience, 1987